Ra capital management buys $25.3 million in Janux therapeutics stock

RA Capital Management, L.P., a significant shareholder in Janux Therapeutics , Inc. (NASDAQ:JANX), has increased its stake in the pharmaceutical company by purchasing additional shares. According to a recent SEC filing, the firm acquired a total of 824,041 shares of Janux Therapeutics common stock over several transactions conducted from March 5 to March 7, 2025. The purchases were made at a price range between $30.56 and $31.30 per share, amounting to a total investment of approximately $25.3 million. The timing is notable as InvestingPro data shows the stock trading near its 52-week low of $29.63, with a market capitalization of $1.83 billion.

RA Capital Management, along with its affiliated entities RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P., now holds a significant portion of Janux Therapeutics’ shares. The transactions reflect the firm’s continued interest in the San Diego-based company, which specializes in pharmaceutical preparations. According to InvestingPro analysis, Janux maintains strong financial health with a current ratio of 59.21, indicating robust liquidity, and holds more cash than debt on its balance sheet.

The filings also note the involvement of key individuals such as Dr. Peter Kolchinsky and Mr. Rajeev Shah, who play crucial roles in RA Capital’s investment strategy. Dr. Kolchinsky, a managing member, signed the filing on behalf of the involved entities. The purchases were made indirectly through RA Capital’s funds, with the shares being held by RA Capital Healthcare Fund and RA Capital Nexus Fund II.

Investors and analysts will be closely watching how these transactions impact Janux Therapeutics’ stock performance and the broader market perception of the company’s growth prospects. Analyst sentiment remains mixed, with price targets ranging from $25 to $200 per share. For deeper insights into Janux’s valuation and 13 additional ProTips, consider subscribing to InvestingPro.

In other recent news, Janux Therapeutics has been the subject of multiple analyst reviews, highlighting its ongoing developments and potential in the oncology market. Cantor Fitzgerald reiterated an Overweight rating with a $200 price target, focusing on the progress of Janux’s ’007 therapy in various patient groups. The company is refining Phase 3 protocols and exploring new dosing regimens, such as bi-weekly and subcutaneous delivery methods, to improve patient access. BTIG maintained a Buy rating with a $100 price target, emphasizing Janux’s competitive positioning with JANX007 in metastatic castration-resistant prostate cancer (mCRPC) and its favorable PSA response rates. The analyst noted the company’s plans to advance dosing regimens for improved convenience.

Clear Street initiated coverage with a Buy rating and an $80 price target, citing optimism about Janux’s prospects in the oncology sector. The firm’s coverage praised JANX007’s potential to disrupt the prostate cancer market, which is valued at approximately $5 billion. Clear Street also anticipates significant data readouts in the coming years that could further enhance Janux’s position in the oncology drug market. These recent developments underscore the ongoing interest and confidence in Janux Therapeutics’ clinical strategies and product pipeline from multiple analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.